
    
      The study is a prospective, randomized, parallel group, double-blind, placebo-controlled
      study to confirm the efficacy and the safety of the oxytocin receptor antagonist, nolasiban,
      in 760 women undergoing fresh embryo transfer following in vitro fertilisation (IVF) or
      intra-cytoplasmic sperm injection (ICSI).
    
  